The incidence of venous thromboembolism after curative colon cancer surgery within an enhanced recovery after surgery programme
Based on three randomised controlled trials performed more than a decade ago, several national guidelines recommend prolonged venous thromboprophylaxis for 28 days following elective surgery for colon cancer. None of these studies were conducted within enhanced recovery after surgery setting. Newer studies indicate that prolonged prophylaxis might not be necessary with enhanced recovery after surgery. We aimed to provide further evidence to this unreso lved discussion. (Source: Thrombosis Research)
Source: Thrombosis Research - March 15, 2024 Category: Hematology Authors: Niklas Nygaard Baastrup, Astrid Kerstine Buch, Anders Kierkegaard Gundestrup, Anna Sofie Friis Olsen, Jakob Kleif, Issam Al-Najami, Ulrik Deding, Claus Anders Bertelsen, COMES II Copenhagen cOmplete Mesocolic Excision Study II study group, the Danish Colo Tags: Full Length Article Source Type: research
Cyclophosphamide vs rituximab for eradicating inhibitors in acquired hemophilia A: A randomized trial in 108 patients
Acquired hemophilia A (AHA) is a rare autoimmune disorder due to autoantibodies against Factor VIII, with a high mortality risk. Treatments aim to control bleeding and eradicate antibodies by immunosuppression. International recommendations rely on registers and international expert panels. (Source: Thrombosis Research)
Source: Thrombosis Research - March 14, 2024 Category: Hematology Authors: H. L évesque, J.F. Viallard, E. Houivet, B. Bonnotte, S. Voisin, V. Le Cam-Duchez, F. Maillot, M. Lambert, E. Liozon, B. Hervier, O. Fain, B. Guillet, J. Schmidt, L.E. Luca, M. Ebbo, N. Ferreira-Maldent, A. Babuty, L. Sailler, P. Duffau, V. Barbay, S. Au Source Type: research
Intrinsic coagulant potential modulates anticoagulant efficacy of rivaroxaban
Direct oral anticoagulants (DOAC) revolutionized the management of venous thromboembolic events (VTE) as their route of administration is oral, dosing fixed, and laboratory monitoring considered unnecessary. Rivaroxaban (RVX) is a direct oral factor Xa inhibitor increasingly prescribed also in obese patients [1]. (Source: Thrombosis Research)
Source: Thrombosis Research - March 14, 2024 Category: Hematology Authors: Cindy Pereira Portela, Guido Stirnimann, Dino Kr öll, Alessandro Aliotta, Lucas Veuthey, Maxime G. Zermatten, Lorenzo Alberio, Debora Bertaggia Calderara Tags: Letter to the Editors-in-Chief Source Type: research
Comprehensive investigation of platelet function in patients with cirrhosis
Cirrhosis presents with thrombocytopenia and possibly thrombocytopathy. Previous studies exploring platelet function gave conflicting results and most controversies are explained by the variety of methods employed for investigation. We sought to assess in-vitro the overall platelet function in cirrhosis.We investigated 34 patients by using the following tests. (i)Aggregometry. (ii)Measurement of the content of platelet granules. (iii)Cytometric platelet activation. (iv)Plasmatic markers of in-vivo platelet activation. (Source: Thrombosis Research)
Source: Thrombosis Research - March 14, 2024 Category: Hematology Authors: Anna Lecchi, Giulia Tosetti, Claudia Ghali, Silvia La Marca, Marigrazia Clerici, Lidia Padovan, Eti A. Femia, Massimo Primignani, Vincenzo La Mura, Pietro Lampertico, Flora Peyvandi, Armando Tripodi Source Type: research
Prognostic gene landscapes and therapeutic insights in sepsis-induced coagulopathy
Sepsis is a common and critical condition encountered in clinical practice that can lead to multi-organ dysfunction. Sepsis-induced coagulopathy (SIC) significantly affects patient outcomes. However, the precise mechanisms remain unclear, making the identification of effective prognostic and therapeutic targets imperative. (Source: Thrombosis Research)
Source: Thrombosis Research - March 11, 2024 Category: Hematology Authors: Xiaoli Ran, Jun Zhang, Yinyu Wu, Yunxia Du, Daiqin Bao, Haoyu Pei, Yue Zhang, Xiaoqiong Zhou, Rui Li, Xu Tang, Han She, Qingxiang Mao Tags: Full Length Article Source Type: research
Aiming for precision: CYP2C19 gene polymorphism and clopidogrel resistance in patients with peripheral artery disease
Antiplatelet therapy with aspirin and/or one of the P2Y12 inhibitors (e.g., clopidogrel, prasugrel, and ticagrelor) is the cornerstone of medical therapy to mitigate the risk of ischemic events in patients with atherosclerotic cardiovascular diseases (ASCVD) [1]. Moreover, dual antiplatelet therapy (DAPT) is the standard of care following percutaneous revascularization of coronary, lower extremity and carotid arteries [2 –4]. Clopidogrel is the most widely used P2Y12 inhibitor but requires hepatic activation by the cytochrome P450 (CYP) 2C19 enzyme [5]. (Source: Thrombosis Research)
Source: Thrombosis Research - March 8, 2024 Category: Hematology Authors: Sina Rashedi, Parham Sadeghipour, Junyang Lou Source Type: research
Asundexian in atrial fibrillation: Can pharmacodynamic data explain the failure?
The phase 3 OCEANIC-AF trial (NCT05643573) of the investigational oral activated factor XI (FXIa) inhibitor asundexian (Bayer, Leverkusen, Germany) tested at the dose of 50 mg has been stopped early due to an inferior efficacy of asundexian versus the control arm (apixaban) for the prevention of strokes and systemic embolisms in patients with atrial fibrillation (AF). This decision is based on the recommendation of the study's independent data monitoring committee ( IDMC) as part of ongoing surveillance [1]. (Source: Thrombosis Research)
Source: Thrombosis Research - March 7, 2024 Category: Hematology Authors: Julie Vassart, Marie Didembourg, Laure Morimont, Clotilde Brisbois, Laurent Jamart, Aur élien Lebreton, François Mullier, Nathalie Donis, Julien Favresse, Jean-Michel Dogné, Jonathan Douxfils Tags: Letter to the Editors-in-Chief Source Type: research
The role of coagulation factors VIII, IX and XI in the prediction and mediation of recurrent thrombotic events in children with non-central venous catheter deep vein thrombosis
The role of elevated coagulation factors VIII (FVIII), FIX, FXI for the prediction of recurrent thrombotic events in children after an index non-central venous catheter (non-CVC) related deep vein thrombosis (DVT) remains unclear. (Source: Thrombosis Research)
Source: Thrombosis Research - March 7, 2024 Category: Hematology Authors: Alessandra Bosch, Kirsten Brunsvig Jarvis, Leonardo R. Brand ão, Yushu Zhou, Jennifer Vincelli, Nour Amiri, Laura Avila Tags: Full Length Article Source Type: research
Risk of thrombosis, hemorrhage and leukemic transformation in patients with myeloproliferative neoplasms: A nationwide longitudinal cohort study
There are few large-scale, population-based studies detailing the risks of thrombosis, hemorrhage, leukemic transformation in patients with myeloproliferative neoplasms (MPNs), including essential thrombocythemia (ET), polycythemia vera (PV), and primary myelofibrosis (PMF). (Source: Thrombosis Research)
Source: Thrombosis Research - March 6, 2024 Category: Hematology Authors: Joon Young Hur, Nayeon Choi, Jung Hye Choi, Jiyeong Kim, Young-Woong Won Source Type: research
Acute and subacute effects of strenuous exercise on platelet aggregation, coagulation and fibrinolysis in patients with stable coronary artery disease
Strenuous exercise may occasionally cause coronary thrombosis with myocardial infarction and sudden cardiac death. (Source: Thrombosis Research)
Source: Thrombosis Research - March 5, 2024 Category: Hematology Authors: Jacobina Kristiansen, Erik L. Grove, T órur Sjúrðarson, Magni Mohr, Steen D. Kristensen, Anne-Mette Hvas Source Type: research
Tigecycline-associated hypofibrinogenemia: A single center, retrospective, controlled study
The objective of our study was to assess changes in fibrinogen levels in patients for hospitalization, comparing two antibiotic episodes (tigecycline and other) within the same patients. (Source: Thrombosis Research)
Source: Thrombosis Research - March 4, 2024 Category: Hematology Authors: O ğuzhan Firat, Emre Kara, Ümit Yavuz Malkan, Kutay Demirkan, Ahmet Çağkan Inkaya Source Type: research
Impact of allele-selective silencing of von Willebrand factor in mice based on a single nucleotide allelic difference in von Willebrand factor
Von Willebrand factor (VWF) plays a pathophysiological role in hemostatic disorders. Partial inhibition of the VWF gene through small interfering RNA (siRNA)-mediated allele-selective silencing could be a promising therapeutic strategy. For von Willebrand disease, allele-selectively inhibiting dominant-negative VWF-alleles might ameliorate the phenotype. For thrombotic disorders, partial VWF reduction can lower thrombotic risk, while avoiding bleeding. Previously, we demonstrated the feasibility of Vwf-silencing in homozygous C57BL/6J (B6) or 129S1/SvImJ (129S) mice. (Source: Thrombosis Research)
Source: Thrombosis Research - March 4, 2024 Category: Hematology Authors: Yvonne K. Jongejan, Noa A. Linthorst, Elisa Schrader Echeverri, Sebastiaan N.J. Laan, Richard J. Dirven, James E. Dahlman, Bart J.M. van Vlijmen, C écile V. Denis, Jeroen C.J. Eikenboom Source Type: research
Fundamental considerations for designing endothelialized in vitro models of thrombosis
Endothelialized in vitro models for cardiovascular disease have contributed greatly to our current understanding of the complex molecular mechanisms underlying thrombosis. To further elucidate these mechanisms, it is important to consider which fundamental aspects to incorporate into an in vitro model. In this review, we will focus on the design of in vitro endothelialized models of thrombosis. Expanding our understanding of the relation and interplay between the different pathways involved will rely in part on complex models that incorporate endothelial cells, blood, the extracellular matrix, and flow. (Source: Thrombosis Research)
Source: Thrombosis Research - March 4, 2024 Category: Hematology Authors: Titus P. Lemmens, Vanessa Br öker, Minke Rijpkema, Christopher C.W. Hughes, Leon J. Schurgers, Judith M.E.M. Cosemans Tags: Review Article Source Type: research
Platelet factor 4 promotes deep venous thrombosis by regulating the formation of neutrophil extracellular traps
This study is aimed to explore the role of NETs and their interaction with platelet factor 4 (PF4) in DVT. In plasma samples from 51 healthy volunteers and 52 DVT patients, NET markers and PF4 were measured using enzyme-linked immunosorbent assays (ELISA). NET generation in blood samples from healthy subjects and DVT patients was analyzed by confocal microscopy and flow cytometry. (Source: Thrombosis Research)
Source: Thrombosis Research - March 4, 2024 Category: Hematology Authors: Wenqiang Li, Decai Chi, Shuai Ju, Xinyi Zhao, Xiaoyan Li, Junjie Zhao, Huiqi Xie, Yao Li, Jiaqi Jin, Ge Mang, Zhihui Dong Tags: Full Length Article Source Type: research
Effects of gender affirming hormone therapy with testosterone on coagulation and hematological parameters in transgender people assigned female at birth: A systematic review and meta-analysis
Hormone replacement therapy is associated with an increased thromboembolic risk. The effects of testosterone (T) on coagulation markers in people assigned female at birth (AFAB) under gender affirming hormone therapy (GAHT) are not well described. (Source: Thrombosis Research)
Source: Thrombosis Research - March 3, 2024 Category: Hematology Authors: Daniele Tienforti, Daniele Pastori, Arcangelo Barbonetti Source Type: research
